The latest articles from BioStock
» The puzzle pieces are in place in Japan for OssDsign
» Integrum awaits important milestone on the way to commercial breakthrough » Immunicum provides update from the MERECA study
» Follicum reaches milestone in hair study
» CLS has been granted a patent in Japan
» Agreement gives Iconovo long-term revenue potential
Read BioStock's latest Newsletter for week 33 here.
AstraZeneca Imfinzi is now approved in Japan for the treatment of extensive stages of small cell lung cancer. Read more.
Viktor Rydberg's schools equip teachers and other staff with the disinfection solution Hydrocyn aqua from Bactiguard. Read more.
Alzinova announces that the delivery of materials is delayed for the clinical study of the vaccine ALZ-10 on patients with Alzheimer's disease. This is due to further analysis work. Read more.
AlzeCure Pharma will provide a live business update on September 1st. Read more.
Vaccibody have completed patient recruitment in their phase I/IIa cancer vaccine study. Read more.
Reports:
Abliva Aino Health Annexin Pharmaceuticals CombiGene Gentian Diagnostics Glycorex Transplant Iconovo Initiator Pharma Immunovia Isofol Neodynamics Ortivus Contigo Care ProstaLund Scandinavian ChemoTech S2Medical Senzime Surgical Science Kancera Zenicor Medical Systems
Kancera announced that they have received permission to start a covid-19 study with KAND567. Read more.
Acarix published a prospectus in connection with a rights issue of approximately SEK 56 million. Read more.
Genmab announced that FDA has approved the use of DARZALEX (daratumumab) in combination with carfilzomib and dexamethasone for the treatment of adult patients with multiple myeloma. Read moreThe FDA has also approved Genmabs Kesimpta (ofatumumab) in relapsing multiple sclerosis. Read more.
Long-term positive results have been reported with the use of Wasps balloon-expandable covered stents Advanta V12. Read more.
CELLLINK invited to a conference call regarding the acquisition of Science. Read moreThe company also called an extraordinary general meeting. Read more.
Penser Access published an analysis of UsDsign – “Expected dip in the curve during Q2, but growth continues.” Read more.
ADDvise Group announced that they have acquired their own bonds. Read more.
Aqua Bio Technology sent out a notice for an extraordinary general meeting. Read more.
This morning's winner: Eurocine Vaccines 16,15%, Ortivus 12,07%, Aino Health 9,49%, Redwood Pharma 7,49%, AdderaCare 7,14%
This morning's losers: Toleranzia -27,97%, Polarcool -16,81%, Alzinova -13,26%, AlphaHelix -8,05%, Scandinavian ChemoTech -6,39%
Index: OMXS30 1757,98 0,34%, Healthcare 0,1%
More articles from BioStock
» F2G raises $60,8 million for development of antifungal drug
» Biohaven receives billion-dollar cash injection
» Carbiotix diagnostic services are links in the value chain
» Professor Klaus Brasso has high expectations for RhoVacs RV001
» Saniona CEO on the USD 65 million capital raise